Steroids in Duchenne muscular dystrophy--deflazacort trial.

Author: CorderiJ, DubrovskyA L, FloresD, MarcoP, MesaL E

Paper Details 
Original Abstract of the Article :
We conducted a double blind controlled trial in 28 Duchenne muscular dystrophy (DMD) patients with Deflazacort (DF), an oxazoline derivative of prednisolone which reduces its side-effects. Myometric muscle strength measurements, Scott Score and timed tests showed statistically significant improvemen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/0960-8966(91)90099-e

データ提供:米国国立医学図書館(NLM)

Deflazacort: A New Oasis in Duchenne Muscular Dystrophy

The search for [effective treatments for Duchenne muscular dystrophy (DMD)] is an ongoing expedition in [neuromuscular medicine]. This study investigates the potential of [Deflazacort], a derivative of prednisolone, as a therapeutic option for DMD. The researchers aimed to assess the efficacy and safety of Deflazacort in improving muscle strength and reducing side effects in DMD patients.

Deflazacort: A Promising Alternative

The results demonstrate that Deflazacort showed statistically significant improvement in [myometric muscle strength measurements, Scott Score and timed tests] compared to placebo. This suggests that Deflazacort may be a valuable alternative to prednisolone in managing DMD. While some side effects were observed, they were generally mild and manageable.

A Path to Improved Quality of Life: Deflazacort Offers Hope

The study's findings suggest that Deflazacort holds promise as a therapeutic option for DMD, potentially leading to improvements in muscle strength and reduced side effects. This could translate to a better quality of life for patients with this debilitating condition.

Dr.Camel's Conclusion

The journey to treat Duchenne muscular dystrophy is long and arduous. This study offers a glimmer of hope with its findings on the potential benefits of Deflazacort. While more research is needed, this exploration provides a beacon of hope for a more effective and well-tolerated treatment for DMD, paving the way for a brighter future for those navigating this challenging condition.

Date :
  1. Date Completed 1992-09-04
  2. Date Revised 2019-10-22
Further Info :

Pubmed ID

1822804

DOI: Digital Object Identifier

10.1016/0960-8966(91)90099-e

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.